MeiraGTx Holdings (MGTX) Non-Current Deffered Revenue (2017 - 2025)
MeiraGTx Holdings (MGTX) posted Non-Current Deffered Revenue of $65.1 million for Q4 2025, up 1.42% on a QoQ basis from $64.2 million in Q3 2025, and up 13.1% year-over-year from $57.6 million in Q4 2024.
MeiraGTx Holdings (MGTX) Non-Current Deffered Revenue (2017 - 2025) Analysis & Trends
MeiraGTx Holdings' Non-Current Deffered Revenue history runs 9 years deep, the most recent figure standing at $65.1 million for Q4 2025.
- Quarterly Non-Current Deffered Revenue rose 13.1% year-over-year to $65.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $65.1 million (up 13.1% YoY) and the FY2025 annual result came in at $65.1 million, up 13.1% from the prior year.
- Non-Current Deffered Revenue was $65.1 million for Q4 2025 at MeiraGTx Holdings, up from $64.2 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $65.1 million in Q4 2025 and bottomed at $15.5 million in Q3 2022.
- A 5-year average of $42.2 million and a median of $41.2 million in 2021 frame the typical range for Non-Current Deffered Revenue.
- Annual changes were most pronounced in 2022 — Non-Current Deffered Revenue slumped 52.33% — and 2024, when it surged 153.99%.
- MeiraGTx Holdings' Non-Current Deffered Revenue stood at $43.0 million in 2021, then sank by 36.26% to $27.4 million in 2022, then advanced by 23.99% to $34.0 million in 2023, then jumped by 69.26% to $57.6 million in 2024, then grew by 13.1% to $65.1 million in 2025.
- Business Quant data shows MGTX's Non-Current Deffered Revenue at $65.1 million in Q4 2025, $64.2 million in Q3 2025, and $63.0 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | MeiraGTx Holdings | 973.21 Mn | 907.27 Mn | - | 65.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 65.12 Mn |
| Sep 30, 2025 | 64.21 Mn |
| Jun 30, 2025 | 63.04 Mn |
| Mar 31, 2025 | 59.62 Mn |
| Dec 31, 2024 | 57.58 Mn |
| Sep 30, 2024 | 58.90 Mn |
| Jun 30, 2024 | 53.76 Mn |
| Mar 31, 2024 | 53.33 Mn |
| Dec 31, 2023 | 34.02 Mn |
| Sep 30, 2023 | 23.19 Mn |
| Jun 30, 2023 | 25.36 Mn |
| Mar 31, 2023 | 26.43 Mn |
| Dec 31, 2022 | 27.44 Mn |
| Sep 30, 2022 | 15.49 Mn |
| Jun 30, 2022 | 21.34 Mn |
| Mar 31, 2022 | 37.28 Mn |
| Dec 31, 2021 | 43.05 Mn |
| Sep 30, 2021 | 32.49 Mn |
| Jun 30, 2021 | 39.33 Mn |
| Mar 31, 2021 | 43.30 Mn |